Pharmacists belong in dermatology care. We're building the specialty.
We are the professional home for pharmacists in dermatology, and an advocate for expanding their scope of practice. Two billion people live with a skin condition, dermatology appointments take over a month, and pharmacists are the most accessible clinicians. Read the full case.
Sources: World Health Organization, 78th World Health Assembly resolution on skin diseases (2025); see the full case for appointment-wait and pharmacy-access citations.
A professional home, and a voice, for pharmacists in dermatology.
Members learn, connect, and set the Society's priorities. The Society builds the specialty's infrastructure and makes the evidence-based case for the pharmacist's role in skin health.
About the Society →Advocate
We make the case, with citations, for a larger pharmacist role in dermatology: scope of practice, patient access, and recognition of the specialty.
Why I started this
Patients with a skin problem wait weeks for a dermatologist, and many never see one. Pharmacists are the most accessible clinicians they have, and in places like Ontario, pharmacists can already prescribe for conditions such as acne, dermatitis, and impetigo. In most of the U.S. that role isn't recognized yet, and dermatology is barely organized as a specialty within pharmacy.
I started the Society to change that: to connect pharmacists across every side of dermatology (community practice, specialty and compounding, industry) who had nowhere to talk to each other, and to build the training, evidence, and standards that make the case for a larger role. It matters for another reason too. The multibillion-dollar beauty and wellness industry is largely unregulated, and misinformation fills the space where clinical guidance should be. Pharmacists are well placed to be the evidence-based voice.
Help shape what's next
Members shape our priorities and our resource library.
Built by and for the specialty.
Topical Corticosteroid Selector
Rank potency by body site, severity, and patient age, with the reasoning behind each recommendation.
Topical Corticosteroid Potency: A Quick-Reference Framework
Matching potency to site and condition, and knowing when to step down.
The Triamcinolone Shortage: A Case Study in Compounding's Regulatory Edge
A dermatology workhorse that's been on the FDA shortage list for years.
Apremilast, Explained Like an MSL Would
Mechanism, trial data, and where it actually fits in the treatment ladder.
Building Dermatology Pharmacy: The Case for a Specialty
The access gap, why pharmacists, and the regulatory precedent in Ontario, Idaho, and Tennessee.